Publication | Closed Access

EGFR tyrosine kinase inhibitor (TKI) in patients with advanced non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutations: A real-world study in China

OncologyMedicinePathologyCancer GenomicsUncommon Egfr MutationsReal-world StudyCancer TreatmentCancer GeneticsMolecular DiagnosticsRadiation OncologyLung Cancer